IP Library Granted Patent US 10,537,540
Granted Patent B2
US 10,537,540 · App. 14/418,009 · Granted Jan 21, 2020

Pharmaceutical composition for promoting nerve injury restoration and application thereof

Inventors: Maoxing Yue (Beijing, CN); Honggui Wan (Jiangsu, CN); Tongge Huang (Jiangsu, CN)
Assignee: Tongge Huang
A61K31/198A61K31/4415
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,537,540
App. No.
14/418,009
Granted
Jan 21, 2020
Kind
B2
Abstract

A pharmaceutical composition for promoting nerve injury restoration and a use thereof are disclosed. Each unit of the pharmaceutical composition contains 0.5 to 8 g of L-ornithine, 1 to 5 g of aspartic acid, 3 to 10 g of arginine and 3 to 10 g of vitamin B 6 . The pharmaceutical composition can significantly promote recovery of the spinal nerve function, and particularly has a good therapeutic effect on acute myelitis.

Claims (14)

1. A method for treating a subject having acute myelitis, comprising

administering a pharmaceutical composition to the subject having acute myelitis,

wherein the pharmaceutical composition comprises 0.5 to 8 g of L-ornithine, 1 to 5 g of aspartic acid, 3 to 10 g of arginine, 3 to 10 g of vitamin B 6 , with the rest being an excipient and/or other ingredients.

2. The method according to claim 1 , wherein the pharmaceutical composition further comprises one or more substances selected from the group consisting of isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, histidine, glycine, alanine, proline, asparagine, cysteine, glutamic acid, serine, tyrosine, vitamin B 1 , vitamin B 2 , pantothenic acid, biotin, folic acid, vitamin B 12 , and vitamin C.

3. The method according to claim 1 , wherein the pharmaceutical composition further comprises 3 to 10 g of isoleucine, 5 to 15 g of leucine, 3 to 10 g of lysine, 0.5 to 3 g of methionine, 0.5 to 3 g of phenylalanine, 3 to 10 g of threonine, 0.5 to 3 g of tryptophan, 5 to 15 g of valine, 3 to 8 histidine g, 3 to 8 g of glycine, 3 to 10 g of alanine, 3 to 8 g of proline, 0.1 to 3 g of asparagine, 0.1 to 3 g of cysteine, 3 to 10 g of glutamic acid, 0.5 to 5 g of serine, and 0.1 to 3 g of tyrosine; and the contents of the B vitamins are: 1 to 2 mg vitamin B 1 , 1 to 2 mg vitamin B 2 , 3 to 5 mg pantothenic acid, 0.1 to 0.2 mg of biotin, 0.1 to 0.4 mg of folic acid, 2 to 6 μg of vitamin B 12 , and 1 to 3 g of vitamin C.

4. The method according to claim 1 , wherein the composition further comprises vitamin C.

5. The method according to claim 4 , wherein the composition further comprises one or more of vitamin B 1 , vitamin B 2 , and vitamin B 12 .

6. The method according to claim 1 , wherein the pharmaceutical composition further comprises an amount of 5% glucose and sodium chloride injection, or 0.9% sodium chloride injection.

7. The method according to claim 1 , wherein the pharmaceutical composition is in the form of granules, tablets, capsules, or injections.

8. The method according to claim 1 , wherein the subject has inflammation indicated by increased cells in cerebrospinal fluid.

9. The method according to claim 1 , wherein L-ornithine is present in the composition in an amount in a range of from 0.5 to 4.5 g.

10. The method according to claim 1 , wherein vitamin B 6 is present in the composition in an amount in a range of from 5 to 10 g.

11. The method according to claim 1 , wherein the subject is also under treatment with corticosteroids.

12. The method according to claim 1 , wherein the subject is also under treatment with corticosteroids, immunoglobulin, or immunosuppressive therapy.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2016
From: YUE, MAOXING; WAN, HONGGUI; HUANG, TONGGE
To: HUANG, TONGGE
Reel/Frame 037508/0467 →
Priority Claims (1)
CN 2012 1 0272724 · Aug 1, 2012 · national
Continuity (1)
Related Publication 20150335627A1 · Nov 26, 2015